Recent preclinical and clinical studies have highlighted that targeting the GDF15‐GFRAL signalling pathway is a promising approach for treating obesity, particularly because it has minimal impact on skeletal muscle mass, which is essential to preserve during weight loss. The gene discussed is GFRAL; the disease is obesity due to melanocortin 4 receptor deficiency.